DeepMed Research

Fluvax

Generic Name: Fluvax

Clinical Trials

Vaccine Responses in Patients With B Cell Malignancies

Phase 4

Recruiting

Conditions: Lymphoma

Interventions: Biological: Fluzone
Biological: Shingrix
Biological: Flucelvax
Biological: Afluria
Biological: PREVNAR 13
Biological: Heplisav -B
Biological: Pfizer-COVID-19 Vaccine
Biological: FluLaval
Biological: Fluarix
Biological: PNEUMOVAX 23
Drug: PREVNAR 20
Drug: AREXVY, ABRYSVO

First Posted Date: 2021-12-28

Last Posted Date: 2025-04-10

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Target Recruit Count: 500

Registration Number: NCT05170399

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Prev
1
Next

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy